Pyruvate kinase in muscle extracts of the sea mussel Mytilus edulis L.
Explore the source record for details and available documents.
SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Initial velocity and product inhibition studies of Mn2+-activated and FDP-modified Mg2+-activated pyruvate kinase from Concholepas concholepas, were performed. Evidence is presented to show that the Mn2+-enzyme catalyzes an ordered sequential mechanism, with ADP being the first substrate and pyruvate the last product. The results presented are consistent with a random combination of reactants with the FDP-modified Mg2+-activated enzyme and the formation of the dead-end complexes enzyme ADP-ATP and enzyme-PEP-ATP.
1. Kinetic and regulatory properties of pyruvate kinase have been studied in haemolysates of erythrocytic populations from blood and bone marrow of rats. 2. Pyruvate kinase from normal rat erythrocytes showed sigmoidal kinetics vs phosphoenolpyruvate. In contrast, the enzyme from reticulocytes and erythroid-rich bone marrow cells behaved as hyperbolic. 3. The enzyme activities were always inhibited by ATP. Activation by fructose-1,6-bisphosphate was only observed in erythrocytes. 4. These kinetic differences suggest changes in pyruvate kinase isozymes in cells of the erythrocytic line of rats.
1. 5-HT (10(-4) M) had no effect on the activity of phosphofructokinase in Hymenolepis diminuta. Concentrations of ATP above 33 microM inhibited PFK activity; AMP and cyclic AMP relieved this inhibition. 2. Local levels of cyclic AMP may be indirectly modulated by NaF, guanylyl imidophosphate, or 5-HT in the presence of GTP, which stimulates adenylyl cyclase activity x2 in H. diminuta homogenates. 3. Fructose 2,6-bisphosphate (F2BP), a physiological regulator of PFK activity in rat liver, also relieved ATP-induced inhibition of PFK. F2BP was present in supernatants from the worms at about 20 mumol/g wet wt. 4. 5-HT may cause an increase in the rate of glycolysis in H. diminuta by elevating either cyclic AMP and/or AMP levels; these nucleotides can in turn increase PFK activity.
1. The concentration of glycogen, glucose 1,6-P2, fructose 2,6-P2 and the content of glycogen phosphorylase, phosphofructokinase, 6-phosphofructo 2-kinase and glucose 1,6-P2 phosphatase activity, have been determined in rat muscles which differ in their fiber composition: extensor digitorum longus, gastrocnemius, diaphragm and soleus. 2. Glucose 1,6-P2 concentration seems to be related to the glycolytic capacity of the muscle, while fructose 2,6-P2 concentration does not. 3. No significant relationship exists between the fiber type and the content in glucose 1,6-P2 phosphatase and 6-phosphofructo 2-kinase activities.